Chimeric Antibody Market Report 2026

Chimeric Antibody Market Overview

• Chimeric Antibody market size has reached to $13.74 billion in 2025 • Expected to grow to $23.73 billion in 2030 at a compound annual growth rate (CAGR) of 11.5% • Growth Driver: Increasing Prevalence Of Cancer Fueling The Growth Of The Market Due To Rising Lifestyle-Related Risks • Market Trend: Targeted Immune Modulation Reduces Excessive Inflammatory Responses • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chimeric Antibody Market?

Chimeric antibody refers to a laboratory-engineered monoclonal antibody that combines the variable (antigen-binding) region from a non-human species, usually a mouse, with the constant region of a human antibody. This design improves compatibility with the human immune system while maintaining high target specificity. The main types of chimeric antibody are immunoglobulin G (IgG) chimeric antibodies, fragment antigen-binding (Fab) chimeric antibodies, and single-chain variable fragment (ScFv) chimeric antibodies. Immunoglobulin G (IgG) chimeric antibodies are engineered by combining the variable region from one species with the constant region of human IgG to reduce immunogenicity while retaining antigen specificity. They are produced using various manufacturing processes such as recombinant deoxyribonucleic acid (DNA) technology, hybridoma technology, phage display technology, and transgenic technology, and are administered via different routes, including intravenous (IV), subcutaneous, and intramuscular administration. They are used in various applications such as cancer therapy, autoimmune diseases, infectious diseases, and transplant rejection, with key end users including pharmaceutical companies, research institutes, clinics and hospitals, and diagnostic laboratories.

What Is The Chimeric Antibody Market Growth Forecast?

The chimeric antibody market size is expected to see rapid growth in the next few years. It will grow to $23.73 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to advancement in antibody engineering techniques, rising approvals of biologic drugs, expansion of personalized medicine, increasing investment in biopharmaceutical r&d, growing clinical pipeline of chimeric antibodies. Major trends in the forecast period include rising adoption of chimeric antibodies in oncology therapies, increasing use in autoimmune and inflammatory disease treatment, growing demand for target-specific monoclonal antibody therapies, expansion of recombinant dna and phage display technologies, improved safety and reduced immunogenicity compared to murine antibodies.

Global Chimeric Antibody Market Segmentation

1) By Type Of Antibody: Immunoglobulin G Chimeric Antibodies, Fragment Antigen-Binding Chimeric Antibodies, Single-Chain Variable Fragment Chimeric Antibodies 2) By Manufacturing Process: Recombinant Deoxyribonucleic Acid (DNA) Technology, Hybridoma Technology, Phage Display Technology 3) By Mode Of Administration: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration 4) By Application: Cancer Therapy, Autoimmune Diseases, Infectious Diseases, Transplant Rejection 5) By End User: Pharmaceutical Companies, Research Institutes, Clinics And Hospitals Subsegments: 1) By Immunoglobulin G Chimeric Antibodies: Full Length Immunoglobulin G (IgG), Engineered Immunoglobulin G 1 (IgG1), Engineered Immunoglobulin G4 (IgG4) 2) By Fragment Antigen-Binding Chimeric Antibodies: Bivalent Fragment Antigen-Binding (Fab) Fragments, Monovalent Fragment Antigen-Binding (Fab) Fragments, Conjugated Fragment Antigen-Binding (Fab) Fragments, Pegylated Fragment Antigen-Binding (Fab) Fragments 3) By Single-Chain Variable Fragment Chimeric Antibodies: Standard Single-Chain Fragment Variable, Tandem Single-Chain Fragment Variable, Bispecific Single-Chain Fragment Variable, Multivalent Single-Chain Fragment Variable

What Is The Driver Of The Chimeric Antibody Market?

The increasing prevalence of cancer is expected to propel the growth of the chimeric antibody market going forward. Prevalence of cancer refers to the total number of people, both newly diagnosed and previously diagnosed, who are alive with a history of cancer at a specific point in time. The prevalence of cancer is increasing due to lifestyle-related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. Chimeric antibodies enhance cancer treatment strategies by offering targeted therapies, making them effective against specific tumor cells. They reduce side effects by precisely attacking malignant cells, improving patient outcomes and treatment efficiency. For instance, in October 2025, according to National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the chimeric antibody industry.

Key Players In The Global Chimeric Antibody Market

Major companies operating in the chimeric antibody market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Merck KGaA, BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc.

Global Chimeric Antibody Market Trends and Insights

Major companies operating in the chimeric antibody market are focusing on advanced therapies, such as monoclonal antibodies, to improve treatment outcomes, enhance patient survival rates, and address critical medical conditions. Monoclonal antibodies refer to laboratory-engineered proteins that mimic the immune system's ability to fight harmful pathogens, including viruses and inflammatory agents. For instance, in June 2023, InflaRx N.V., a Germany-based biopharmaceutical company, commercially launched Gohibic (vilobelimab). It is a chimeric monoclonal antibody that targets C5a in the complement system, blocking C5a-mediated immune responses to reduce excessive inflammation, and is used for the treatment of COVID-19 in hospitalized adults when administered within 48 hours of initiating invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). This innovative therapy represents a significant advancement in targeting hyperinflammation in severe infections, offering a new treatment option for high-risk patients.

What Are Latest Mergers And Acquisitions In The Chimeric Antibody Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. With this acquisition, Pfizer aims to boost its oncology portfolio with Seagen’s ADC technology, approved cancer therapies, and promising late-stage candidates. Seagen Inc. is a US-based biopharmaceutical company developing chimeric antibody-based cancer therapies.

Regional Insights

North America was the largest region in the chimeric antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chimeric Antibody Market?

The chimeric antibody market consists of sales of biosimilars of chimeric antibodies, diagnostic chimeric antibodies, and therapeutic chimeric antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chimeric Antibody Market Report 2026?

The chimeric antibody market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chimeric antibody industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.